Ximelagatran was noninferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p39
Academic Journal
The article analyses if ximelagatran is noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation (AF) at risk for ischemic stroke. 3410 patients at 18 years of age who had nonvalvular AF and less than or equal to 1 additional risk factor for stroke treatment for hypertension but blood pressure were examined. Secondary outcomes included composite endpoints of major and minor bleeding, ischemic stroke, and systemic embolism. Ximelagatran was not inferior to warfarin for stroke and systemic embolism, or for the secondary outcomes.


Related Articles

  • Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation. Levi, Marcel // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p19 

    This article presents information on a study related to ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Ximelagatran was noninferior to warfarin for preventing the composite endpoint of stroke or systemic embolism. The groups did not differ...

  • Direct Thrombin Inhibitors Soon Available to Prevent Stroke in Atrial Fibrillation Patients. Fink, Matthew E. // Neurology Alert;Nov2011, Vol. 30 Issue 3, p20 

    The article discusses the addition of two direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF) was designed to test rivaroxaban in a double blind trial against warfarin. Also, Apixaban versus...

  • CARDIAC EVALUATION OF PATIENTS WITH ISCHEMIC STROKE. Haider, Iqbal; Khan, Adnan; Iqbal, Naveed; Subhan, Fazli; Muhammad, Iftikhar; Ajmal, Fahad // Khyber Medical University Journal;Jan2012, Vol. 4 Issue 1, p9 

    Objective: To identify the commonest potential cardiac sources of embolism in patients with ischemic stroke. Methodology: This hospital based descriptive case study was conducted at Khyber Teaching Hospital, Peshawar from November 2009 to December 2010 on 150 patients with first ever ischemic...

  • Ablation of atrial fibrillation with the Epicor system: a prospective observational trial to evaluate safety and efficacy and predictors of success. Schopka, Simon; Schmid, Christof; Keyser, Andreas; Kortner, Ariane; Tafelmeier, Julia; Diez, Claudius; Rupprecht, Leopold; Hilker, Michael // Journal of Cardiothoracic Surgery;2010, Vol. 5, p34 

    Background: High intensity focused ultrasound (HIFU) energy has evolved as a new surgical tool to treat atrial fibrillation (AF). We evaluated safety and efficacy of AF ablation with HIFU and analyzed predictors of success in a prospective clinical study. Methods: From January 2007 to June 2008,...

  • Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Currie, C. J.; Jones, M.; Goodfellow, J.; McEwan, P.; Morgan, C. L.; Emmas, C.; Peters, J. R. // Heart;Feb2006, Vol. 92 Issue 2, p196 

    Objective: To compare survival and adverse outcome of patients with non-valvar atrial fibrillation (NVAF) treated with or without warfarin. Design: Record linkage method to identify patients with a previous hospital diagnosis of atrial fibrillation and to link these patients to international...

  • Cardiovascular highlights from non-cardiology journals. Bradley, Steven M. // Heart;Mar2015, Vol. 101 Issue 5, p408 

    A review is offered for the articles "Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction" by TM Maddox and others, and "Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial" by VY Reddy and others, that were published...

  • Cardiovascular highlights from non-cardiology journals. Lindsay, Alistair // Heart;Feb2013, Vol. 99 Issue 3, p214 

    The article presents information on a study related to the benefits of anticoagulant apixiban over warfarin in the treatment of atrial fibrillation. R.D. Lopes et al attempted to find out the results of anticoagulation with apixiban depending on the patients' baseline risk of ischaemic events....

  • Treatment of atrial fibrillation. Abhay Bajpai; Irina Savelieva; A. John Camm // British Medical Bulletin;Dec2008, Vol. 88 Issue 1, p75 

    Introduction Atrial fibrillation (AF) is the most common, sustained rhythm disturbance. The prevalence of AF is increasing as people live longer. Common conditions such as hypertension and ischaemic heart disease play an important role in the development of AF. The presence of AF is associated...

  • Right Atrial Thrombus Mimicking Myxoma with Subclinical Pulmonary Embolism. Artemiou, P.; Lukacin, S.; Bily, B. // Cardiovascular Journal;2013, Vol. 6 Issue 1, p71 

    We reported a case of right atrial thrombosis mimicking myxoma in a patient with atrial fibrillation and subclinical pulmonary embolism. The definite diagnosis was made postoperatively. While sometimes the diagnosis is challenging, these patients are at high risk for pulmonary embolism and they...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics